Tools for Monitoring and Managing Inappetence

These downloadable tools are provided to help you, your staff and pet owners recognize inappetence and how you can use ENTYCE® (capromorelin oral solution) as a therapeutic solution for stimulating appetite in your canine patients.

ENTYCE Dosing Chart

Dosing Chart

ENTYCE is a once-daily oral solution. The drug concentration is 30 mg/mL with the recommended dose of 3 mg/kg (1.4 mg/lb). See this ENTYCE Dosing Chart for appropriate dosing based on the weight of your canine patient.

Download PDF >

Inappetence Overview Sheet

Inappetence Overview Sheet

Early recognition of changes in a canine’s appetite is important to allow the veterinarian to diagnose and treat the underlying cause. Check out this resource to review the signs, multitude of causes and impact of inappetence.

Download PDF >

Pet Owner Inappetence Questionnaire

Pet Owner Inappetence Questionnaire

This quick, 5-question sheet is designed to help pet owners identify and monitor any changes in eating behavior that may warrant a discussion with you.

Download PDF >

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

Other therapeutics from Aratana

Nocita® (bupivacaine liposome injectable suspension)
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls post-op pain with one dose at the source for up to 72 hours following canine cranial cruciate ligament surgery or feline onychectomy to help patients recover comfortably. 

Visit Website >

DOG INDICATION: For single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs only. Do not use in dogs younger than 5 months of age, that are pregnant, lactating or intended for breeding. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

CAT INDICATION: For use as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use as a peripheral nerve block in cats only. Do not use in cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding. Do not administer by intravenous or intra-arterial injection. Adverse reactions in cats may include elevated body temperature, infection or chewing/licking at the surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.